Skip to main content
. 2021 Jan 11;6(1):e140848. doi: 10.1172/jci.insight.140848

Figure 5. Opposing effects of vasopressin receptors in fructose-induced metabolic syndrome.

Figure 5

(A) 30-week cumulative total and fructose-derived caloric intake in WT (black), V1aR-KO (ochre), and V1bR-KO (green) mice on 10% fructose. (B) Serum copeptin levels in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution for 30 weeks. (C) Weekly body weight gain in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution for 30 weeks. (D) Representative H&E images from livers of mice (n > 10 images per animal) of the same groups as in A at 30 weeks. Size bars: 50 μM. (E) Liver triglycerides (normalized to protein levels) at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. (F) Serum ALT levels at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. (G) Serum insulin levels at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. (H) Serum leptin levels at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. (I) Representative H&E images from epididymal adipose tissue of mice (n > 10 images per animal) of the same groups as in A at 30 weeks. Size bars: 50 μM. (J) Total fat mass (g) at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. (K) Fat mass to total body weight percentage at 30 weeks in WT, V1aR-KO, and V1bR-KO mice receiving a 10% fructose solution. The data in A–C, E–H, and J and K are presented as the mean ± SD and analyzed by 1-way ANOVA with Tukey’s post hoc analysis. *P < 0.05, **P < 0.01. n = 6 mice per group. See also Supplemental Table 5. V1aR, vasopressin 1a receptor; V1bR, vasopressin 1b receptor; PT, portal triad; CV, central vein; ALT, alanine aminotransferase.